Enjoy complimentary customisation on priority with our Enterprise License!
The alcoholic hepatitis treatment market share is expected to increase by USD 695.42 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 6.39%. This alcoholic hepatitis treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The alcoholic hepatitis treatment market report also offers information on several market vendors, including Cadila Healthcare Ltd., Dr. Reddys Laboratories Ltd., Gilead Sciences Inc., Johnson & Johnson, Mylan NV, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. among others. Furthermore, this report extensively covers alcoholic hepatitis treatment market segmentation by type (corticosteroids, xanthine derivatives, and others) and geography (North America, Europe, Asia, and ROW).
Download the Free Report Sample to Unlock the Alcoholic Hepatitis Treatment Market Size for the Forecast Period and Other Important Statistics
The increasing consumption of alcohol worldwide is notably driving the alcoholic hepatitis treatment market growth, although factors such as lack of therapies to treat severe alcoholic hepatitis may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the alcoholic hepatitis treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Alcoholic Hepatitis Treatment Market Driver
Increasing consumption of alcohol worldwide is a major driver fueling the alcoholic hepatitis treatment market growth. Heavy consumption of alcohol leads to alcoholic hepatitis, which results in hepatic encephalopathy. There has been an increase in the consumption of alcohol globally, which resulted in increased cases of alcoholic hepatitis and mortality rates. In 2017, according to Our World in Data, worldwide alcohol disorders had the highest death toll of 184,934 due to substance use disorders. Brazil, Sub-Saharan Africa, China, India, Russia, and the US, among others, were the countries that observed a high death rate due to alcohol use disorders. Also, every year, 21,815 deaths are caused by alcohol liver diseases in the US. Furthermore, in 2016, a total of 2,744,248 resident deaths were registered in the US. Similarly, according to Eurostat, in wine-producing countries such as Spain, Italy, and Portugal, people tend to drink daily. According to Eurostat, in 2016, 18.6 liters of pure alcohol were consumed per person in Lithuania, followed by Romania (13.7 liters), Bulgaria (13.6 liters), and Belgium (13.2 liters). The COVID-19 pandemic resulted in lockdowns. With the orders of stay at home or work-from-home, the consumption of alcohol spiked in some cities of the US and India. Growing consumption of alcohol is increasing the risk of alcoholic hepatitis. This will drive the global alcoholic hepatitis treatment market during the forecast period.
Key Alcoholic Hepatitis Treatment Market Trend
The development of combination therapies to treat severe alcoholic hepatitis is a major trend influencing the alcoholic hepatitis treatment market growth. The market has witnessed the development of combination therapies to treat severe alcoholic hepatitis. Currently, there is no effective treatment for severe alcoholic hepatitis. Therefore, researchers are focusing on developing combination therapies, as they are more effective. For instance, the researchers at the University of Massachusetts Medical School are studying a combination therapy with Kineret, Trental, and zinc sulfate. During the multicenter study, the combination showed short- and long-term survival benefits in patients with severe alcoholic hepatitis with no unexpected treatment-related severe adverse events. Similarly, Gilead Sciences is conducting a Phase II clinical trial to evaluate the safety and tolerability of selonsertib (GS-4997) in combination with prednisolone in patients with severe alcoholic hepatitis. Furthermore, researchers are evaluating an antibiotic combined with a corticosteroid by targeting the group of patients at high risk of death due to alcoholic hepatitis. Also, researchers are conducting a study on N-acetylcysteine and prednisolone combination therapy for people with severe alcoholic hepatitis in order to improve short-term mortality. Such developments of combination therapies are expected to drive the growth of the market during the forecast period.
Key Alcoholic Hepatitis Treatment Market Challenge
The lack of therapies to treat severe alcoholic hepatitis is a major hindrance to the alcoholic hepatitis treatment market growth. There is a lack of therapies to treat severe alcoholic hepatitis, which may pose a challenge to market growth. Only corticosteroids are the main treatment options for severe alcoholic hepatitis. However, several patients have contraindications for steroid treatment. According to Behnam Saberi et al., there is no clear evidence that steroids are effective in the management of alcoholic hepatitis. Corticosteroids are recommended by the American Association for the Study of Liver Disease and the European Association for the Study of Liver as first-line therapy for severe alcoholic hepatitis. However, corticosteroids are associated with several contraindications such as renal failure, active gastrointestinal bleeding, uncontrolled hyperglycemia, and acute pancreatitis. Similarly, pentoxifylline is recommended for people with severe alcoholic hepatitis, if they have contraindications to corticosteroids. However, pentoxifylline has no impact on disease progression. Similarly, etanercept was evaluated in a multicenter study by Boetticher et al. According to the results, the six-month mortality was high in patients treated with etanercept. Also, serious adverse events were significantly high in patients. Another monoclonal antibody, infliximab, in a multicenter study, showed that the probability of death at two months was high in patients. These factors are expected to hinder the growth of the global alcoholic hepatitis treatment market during the forecast period.
This alcoholic hepatitis treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Technavio categorizes the global alcoholic hepatitis treatment market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the alcoholic hepatitis treatment market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the alcoholic hepatitis treatment market encompasses successful business strategies deployed by the key vendors. The alcoholic hepatitis treatment market is concentrated and the vendors are deploying growth strategies such as organic and inorganic strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The alcoholic hepatitis treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the alcoholic hepatitis treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of global pharmaceuticals market includes the following core components:
The report has further elucidated on other innovative approaches being followed by service providers to ensure a sustainable market presence.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Customer landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.